Compare J B Hunt Transport Services Inc (JBHT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? J B Hunt Transport Services Inc trades at $265.38 (market cap $24.92B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.4× J B Hunt Transport Services Inc's market cap, and J B Hunt Transport Services Inc pays a 0.68% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| JBHT | VRTX | |
|---|---|---|
Market Cap | $24.92B | $134.25B |
Sector | Industrials | Health |
52-Week High | $298.41 | $529.65 |
52-Week Low | $130.65 | $376.62 |
Enterprise Value | $26.06B | $128.37B |
Dividend Yield | 0.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
